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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a marked decline in cognition
and memory function. Increasing evidence highlights the essential role of neuroinﬂammatory and
immune-related molecules, including those produced at the brain barriers, on brain immune surveillance,
cellular dysfunction and amyloid beta (Ab) pathology in AD. Therefore, understanding the response at the
brain barriers may unravel novel pathways of relevance for the pathophysiology of AD. Herein, we
focused on the study of the choroid plexus (CP), which constitutes the blood–cerebrospinal ﬂuid barrier,
in aging and in AD. Speciﬁcally, we used the PDGFB-APPSwInd (J20) transgenic mouse model of AD,
which presents early memory decline and progressive Ab accumulation, and littermate age-matched
wild-type (WT) mice, to characterize the CP transcriptome at 3, 5–6 and 11–12 months of age. The most
striking observation was that the CP of J20 mice displayed an overall overexpression of type I interferon
(IFN) response genes at all ages. Moreover, J20 mice presented a high expression of type II IFN genes in
the CP at 3 months, which became lower than WT at 5–6 and 11–12 months. Importantly, along with a
marked memory impairment and increased glial activation, J20 mice also presented a similar overexpres-
sion of type I IFN genes in the dorsal hippocampus at 3 months. Altogether, these ﬁndings provide new
insights on a possible interplay between type I and II IFN responses in AD and point to IFNs as targets for
modulation in cognitive decline.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is the most prevalent form of demen-
tia and is predicted to affect eighty million people worldwide by
2040 (Ballard et al., 2011; Querfurth and LaFerla, 2010). The major
constraint of AD patients is the severe loss of cognitive abilities
(Ballard et al., 2011). Moreover, this neurodegenerative disease is
characterized by two main brain pathological hallmarks: the extra-
cellular deposition of amyloid beta (Ab) peptides, in the form of
senile plaques, and the formation of intracellular neuroﬁbrillary
tangles, as a result of increased aggregation of hyperphosphory-
lated Tau protein (Gotz et al., 2001; Hardy and Selkoe, 2002;
Lewis et al., 2001; Scheuner et al., 1996). The amyloidogenic
hypothesis of AD considers that amyloid pathology may resultfrom increased Ab production, through the amyloidogenic process-
ing of the amyloid precursor protein (APP), and/or decreased excre-
tion of Ab out of the brain (Hardy and Selkoe, 2002; Roberson and
Mucke, 2006). In fact, oligomerization of Ab peptides in the brain
has been described as an early pathogenic event that is responsible
for behavior alterations (Mucke et al., 2000; Palop and Mucke,
2010). However, regardless of the attention given to increased Ab
formation and toxicity in the brain, neuroinﬂammation is also rec-
ognized as an early and essential mediator of brain pathology and
behavior alteration in AD (Lucin and Wyss-Coray, 2009;
Wyss-Coray, 2006). In this context, two relevant emerging con-
cepts should be considered: (I) the age-associated changes in the
blood composition and (II) the levels/ratio of type I and II inter-
feron (IFN) cytokines. Regarding the ﬁrst concept, recent observa-
tions showed the involvement of the systemic milieu in memory
formation and the role of speciﬁc inﬂammatory molecules in
age-related decreased synaptic plasticity and memory function
(Baruch et al., 2013; Villeda et al., 2011). Regarding the second con-
cept, an enhanced type I IFN signaling at the brain barriers, and
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cognitive decline in aged mice (Baruch et al., 2014).
Of relevance, the brain barriers, namely the blood–brain barrier,
composed by the endothelial cells of the blood capillaries, and the
blood–cerebrospinal (CSF) barrier, formed by the choroid plexus
(CP) epithelial cells, seems to inﬂuence both the excretion of Ab
peptides out of the brain (Carro et al., 2002, 2005; Zlokovic,
2008) and the inﬂammatory response (Marques et al., 2009,
2013; Zlokovic, 2008). Particularly, besides its role in the formation
and secretion of the CSF, recent studies clearly indicate that the CP
is able to modulate the cognitive function, through changes in the
neuroinﬂammatory response and in brain immune surveillance
(Baruch et al., 2013, 2014; Baruch and Schwartz, 2013).
Interestingly, the role of the CP in the neuroinﬂammatory response
in AD, as well as its connection with impaired memory and cogni-
tion, is still poorly understood and is addressed in the present
study. Speciﬁcally, we took advantage of a mouse model of AD that
presents early cognitive deﬁcits and brain amyloid pathology, the
PDGFB-APPSwInd (J20) (Mucke et al., 2000), and respective
wild-type (WT) age-matched littermates, to study changes in the
CP transcriptome and in the composition of the CSF.
Furthermore, we analyzed the extension of the changes observed
at the level of the CP, by assessing the neuroinﬂammatory response
at the dorsal hippocampus (dHPC), a brain region that is seriously
affected in AD (Palop et al., 2007; Villeda et al., 2011). Altogether,
the results suggest that alterations in IFN signaling may contribute
to neuroinﬂammation, amyloid pathology and cognitive impair-
ment in aging and in AD.2. Materials and methods
2.1. Ethics statement
Animal handling and experimental procedures were conducted
in accordance with the Portuguese national authority for animal
experimentation, Direção Geral de Veterinária (ID: DGV9457).
Animals were kept in accordance with the guidelines for the care
and handling of laboratory animals in the Directive 2010/63/EU
of the European Parliament and the Council. The animals were
housed and maintained in a controlled environment at 22–24 C
and 55% humidity, on 12 h light/dark cycles and fed with regular
rodent’s chow and tap water ad libitum.2.2. Animal model and experimental groups
Male hemizygous B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2J/Mmjax
(J20) mice, in a C57BL/6J background, ﬁrst developed by Professor
Lennart Mucke, of The J. David Gladstone Institutes (San Francisco,
CA, USA), were purchased from The Jackson Laboratory (Bar
Harbor, Maine, USA). The J20 mice express a mutant form of the
human APP bearing both the Swedish (K670N/M671L) and the
Indiana (V717F) mutations (APPSwInd). Expression of the trans-
genic insert is directed by the human platelet-derived growth fac-
tor beta polypeptide (PDGFB) promoter (Mucke et al., 2000).
Hemizygous mice present the highest expression of the transgene
product in neurons of the neocortex and HPC. At 5–7 months of age
diffuse Ab peptides deposition is detected in the dentate gyrus
(DG) and neocortex. Amyloid deposition is progressive with all
transgenic mice exhibiting plaques by the age of 8–10 months
(Mucke et al., 2000; Palop et al., 2007). Both hemizygous trans-
genic J20 mice and age-matched non-carrier WT littermates (all
males) were used. Male mice were divided, according to age, into
three groups: 3 months, 5–6 months and 11–12 months. These
ages were chosen in order to assess the changes in behavior, at
the blood–CSF barrier and in the brain parenchyma, at differentstages of Ab pathology, particularly before and after Ab plaque for-
mation. The value of achieved power (1b) of the sample was cal-
culated using the IBM SPSS Statistics for Windows (Version 23.0.
Armonk, NY: IBM Corp, USA), on the basis of the sample size
(N = 80) and effect size (partial eta squared = 0.044) associated
with the Morris water maze (MWM) test, which was analyzed by
a parametric repeated measures two-way ANOVA (a = 0.05).
Taking that the Mauchly’s Test revealed a violation of sphericity
for the analyzed groups, the Huynh–Feldt correction was applied
and a ﬁnal value of 1b = 0.841 was obtained, which is considered
to be statistically powerful (Mazen et al., 1985).
2.3. MWM paradigm
Memory was evaluated during the light phase of the diurnal
cycle using the MWM paradigm. The MWM was performed in a
white circular pool (170 cm in diameter and 50 cm in height), ﬁlled
with tap water (23 ± 1 C; 30 cm of depth) and placed in a poorly lit
room. The water tank was divided into four imaginary quadrants
(north, east, south, and west), each corresponding to a ﬁxed extrin-
sic clue visible to the mouse. A transparent escape platform (14 cm
in diameter and 30 cm high), invisible to the mouse, was placed in
the center of one of the quadrants and was maintained in that
same position during the ﬁve days of the acquisition. For spatial
reference-memory acquisition, a HPC-dependent task, the mice
were placed randomly in one of the quadrants in each trial, and
allowed to search for the hidden platform. During the ﬁve days
of the acquisition phase, each mouse performed four trials per
day. Each trial was concluded when the platform was reached
within the time-limit of 120 s. If failing to reach the platform
within this time-period, the mouse was guided to the platform
and allowed to stay in it for 30 s. The four random consecutive tri-
als of each day were video-captured with a video-tracking system
(Viewpoint, Champagne au Mont d’or, France) and the mean values
of the time (latency to platform) and speed to reach the platform
were calculated. To analyze the MWM performance, mice were
divided into groups according to their age and genotype. After
two independent experiments with identical results, the ﬁnal
number of mice per group was the following: at 3 months, N
(WT) = 16 and N (J20) = 8; at 5–6 months, N (WT) = 8 and N
(J20) = 10; at 11–12 months, N (WT) = 23 and N (J20) = 15.
2.4. Tissue sample collection and storage
During the light phase of the diurnal cycle, speciﬁcally in the
morning, mice were anesthetized with an intraperitoneal injection
of a mixture of ketamine hydrochloride (150 mg/kg, Imalgene
1000) and medetomidine hydrochloride (0.3 mg/kg, Dorben).
Under deep anesthesia, CSF samples were collected from the cis-
terna magna and checked for blood contamination using a haemo-
cytometer. Samples were stored at 80 C until further use. After
this, mice were transcardially perfused with 0.9% saline and the
brains were removed from the skull. For gene expression analysis
by microarray and qRT-PCR, the CP samples from each brain ven-
tricle of the same mouse were rapidly removed under a conven-
tional light stereomicroscope (SZX7, Olympus, Hamburg,
Germany), pooled, snap-frozen and stored at 80 C. Speciﬁc brain
areas, namely the dHPC, were obtained by macrodissection,
snap-frozen and stored at 80 C, for RNA extraction and gene
expression analysis. Whole brains were ﬁxed in 4% paraformalde-
hyde (PFA, Panreac Química S.L.U., Barcelona, Spain) for 48 h and
kept in parafﬁn blocks until further sectioning. Alternatively,
brains were immediately embedded in Richard-Allan Scientiﬁc™
Neg-50™ Frozen Section Medium (ThermoFisher Scientiﬁc,
Waltham, MA, USA), snap-frozen and kept frozen at 20 C until
further sectioning.
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Total RNA was extracted from CP tissue using the RNeasy Plus
Micro Kit (Qiagen, Hamburg, Germany), following the manufac-
turer’s instructions. After quality assessment using the Agilent
Bioanalyzer (Agilent Technologies, CA, USA), 500 ng of total RNA
were used for T7-based mRNA ampliﬁcation using the manufac-
tured kit TargetAmp™ 2 – Round Biotin aRNA Ampliﬁcation Kit
3.0 (Epicentre, Illumina, Wisconsin, USA), according to the manu-
facturer’s instructions. The quality of ampliﬁed RNA was assessed
using an Agilent Bioanalyzer. Ampliﬁed RNA was labeled and
hybridized to Illumina Mouse Ref 8 v2.0 gene expression
BeadChips, querying the expression of approximately 25,600
RefSeq-curated gene targets, for microarray analysis by the
Southern California Genotyping Consortium (SCGC) core using
the Illumina BeadStation platform. Statistical microarray analysis
and gene expression analysis were performed at the Informatics
Center for Neurogenetics and Neurogenomics (ICNN) core at
UCLA using R (www.r-project.org) and Bioconductor (www.bio-
conductor.org) packages as described before (Coppola, 2011;
Coppola et al., 2008). The raw data was deposited in the GEO data-
base, accession number GEO: GSE66598. Gene pathway and func-
tional analysis was performed using the Ingenuity Pathway
Analysis 6.0 (IPA; Ingenuity Systems, www.ingenuity.com). The
CP transcriptome of WT mice at 3 (N = 3), 5–6 (N = 4) and 11–12
(N = 6) months, and of J20 mice at 3 (N = 4), 5–6 (N = 4) and 11–
12 (N = 3) months, was analyzed and compared. The individual
data sets consisted on: (I) the comparison between the CP tran-
scriptome of J20 mice and the CP transcriptome of WT mice, at dif-
ferent ages; (II) the comparison between the CP transcriptome of
11–12 months-old mice and that of 3 months-old mice, for each
genotype independently. The data sets containing the accession
numbers, the log ratio and the p-value for each gene, whose
expression was signiﬁcantly changed (p-value < 0.05), were
uploaded into the IPA database. Using IPA and its applications, each
gene identiﬁer was mapped and the genes were used to build net-
works associated with a speciﬁc canonical pathway or with a rele-
vant biological function or disease, according to the IPA database
library. The Ingenuity Upstream Regulator Analysis computed
an activation z-score and a Fisher’s exact p-value (overlap
p-value) for the most altered genes. Furthermore, we used the
IPA Upstream Regulator application to assemble an interactome
using the ﬁve upstream regulators with the highest activation
z-scores and the ﬁve upstream regulators with the lowest activa-
tion z-scores, along with the corresponding downstream target
genes/molecules whose expression was signiﬁcantly altered in
the CP of J20 mice at each age. To be included in the interactome,
the networks had to present at least one connection with an
upstream regulator or with a downstream gene of a different adja-
cent network; orphan networks were not presented.
2.6. Primary cultures of CP epithelial cells and incubation with Ab1–42
Primary cultures of CP epithelial cells were prepared from the
CP tissue of rat pups due to the higher cellular yield of the isolation
procedure when compared to the mouse CP. This procedure was
performed as described before (Marques et al., 2009), with minor
modiﬁcations. Brieﬂy, neonates (P5–P7) were sacriﬁced and the
CP dissected from the four brain ventricles, under a conventional
light stereomicroscope (SZX7, Olympus). The tissue was rinsed in
phosphate buffer saline (PBS, Invitrogen, Carlsbad, CA, USA) with-
out Ca2+ and Mg2+, followed by a 25 min digestion with
0.1 mg/mL pronase (Sigma–Aldrich, St. Louis, MO, USA) at 37 C.
Predigested tissue was recovered by sedimentation and brieﬂy
shaken in 0.025% trypsin–EDTA (Invitrogen) containing 12.5 lg/ml
DNAse I (Roche, Amadora, Portugal). The supernatant was thenwithdrawn and kept on ice with 10% fetal bovine serum (FBS,
Invitrogen). This step was repeated ﬁve times. Cells were collected
by centrifugation and re-suspended in culture media consisting of
Ham’s F-12 and Dulbecco’s modiﬁed Eagle’s medium (DMEM-F12,
Invitrogen) supplemented with 10% FBS, 2 mM glutamine,
50 mg/mL gentamycin, 5 mg/mL insulin, 5 mg/mL transferrin,
5 ng/mL sodium selenite, 10 ng/mL epidermal growth factor,
2 mg/mL hydrocortisone and 5 ng/mL basic ﬁbroblast growth fac-
tor (all from Sigma–Aldrich). For further enrichment, cells were
incubated on plastic dishes for 2 h at 37 C. The supernatant con-
taining the CP epithelial cells was collected and placed for seeding
on 0.4 lm pore size transwells (Corning Life Sciences, Lowell, MA,
USA) coated with laminin (BD Biosciences, Bedford, MA, USA) at a
density of 1  105 cells/cm2. The culture medium was changed
every two days and CP epithelial cells were maintained in culture
for 5–7 days, at 37 C in a humid atmosphere (5% CO2), before per-
forming the experiment. To assess the cellular purity and conﬂu-
ence after 7 days in culture, an immunoﬂuorescent staining was
performed, using a primary antibody for transthyretin (TTR)
(kindly provided by Dr. Maria Joao Saraiva, Institute for
Molecular and Cell Biology, Porto, Portugal), a speciﬁc marker of
CP epithelial cells (Sousa et al., 2007). Cell counting revealed that
P 95% of the cells stained positive for TTR. Stock Ab1–42
(American Peptide Company, Sunnyvale, CA, USA) was prepared
by dissolving the peptides in Tris–NaCl buffer (150 mM NaCl and
50 mM Tris–HCl pH 7.4, all from Sigma–Aldrich) to a ﬁnal concen-
tration of 221.5 lM and kept at 80 C. After reaching conﬂuence,
CP epithelial cells were incubated for 60 h with DMEM-F12 alone
(vehicle) or a solution of 1 lM monomeric/dimeric Ab1–42, by dis-
solving stock Ab1–42 in DMEM-F12 medium.
2.7. Primary cultures of astrocytes and neurons
This procedure was performed as described before (Mesquita
et al., 2014). Details are provided in Supplementary methods
(Appendix A).
2.8. Gene expression analysis by qRT-PCR
The quality assessment and quantiﬁcation of the total RNA
extracted from CP samples was performed in the NanoDrop
ND-1000 and 350 ng of RNA from each sample were ampliﬁed
using the MessageAmp™ II aRNA Ampliﬁcation Kit (Ambion,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Total RNA was also extracted from primary cultures of CP epithelial
cells, using the RNeasy Plus Micro Kit (Qiagen), or from samples of
dHPC, using the Trizol reagent (Invitrogen), following the manufac-
turer’s instructions. Then, after quantiﬁcation in the NanoDrop,
500 ng of total or ampliﬁed RNA from each sample was reverse
transcribed into cDNA using the iScript™ cDNA Synthesis Kit
(Bio-Rad Laboratories, Hercules, CA, USA) following the manufac-
turer’s instructions. Primers used to measure the expression levels
of selected mRNA transcripts by qRT-PCR were designed using the
Primer-BLAST tool of the National Center for Biotechnology
Information (Bethesda, MD, USA) on the basis of the respective
GenBank accession numbers. The reference gene hypoxanthine
guanine phosphoribosyl transferase (Hprt) was used as internal
standard for the normalization of the expression of selected tran-
scripts. All GenBank accession numbers for Mus musculus (in vivo
studies) or Rattus norvegicus (in vitro experiments) gene transcripts
and primer DNA sequences are provided in Supplementary data
(Appendix A). Annealing temperatures are available on request.
The qRT-PCR was performed on a CFX 96TM real-time system
instrument (Bio-Rad), with the SsoFast™ EvaGreen Supermix
(Bio-Rad) according to the manufacturer’s instructions, using equal
amounts of cDNA from each sample. The cycling parameters were
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annealing temperature (primer speciﬁc) for 30 s and 72 C for 30 s,
ﬁnishing with 1 cycle at 65 C to 95 C for 5 s (melting curve).
Product ﬂuorescence was detected at the end of each elongation
cycle. All melting curves exhibited a single sharp peak at the
expected temperature.
2.9. Quantiﬁcation of Ab and IFN-a in the CSF
The quantiﬁcation of Ab in the CSF was performed by a direct
enzyme-linked immunosorbent assay (ELISA) performed in Nunc
MaxiSorp ﬂat-bottom 96-well plates (ThermoFisher Scientiﬁc).
The wells were coated with 1 lL of CSF diluted in 99 lL of a
KH2PO4/K2HPO4 buffer (pH 8.0) solution (1:100 dilution factor),
for 2 h at 37 C. After washing with PBS 0.05% Tween 20
(Sigma–Aldrich), a blocking step with PBS 10% skim milk (Nestle
S.A., Linda-a-Velha, Portugal) was performed for 1 h at
room-temperature (RT). Then, consecutive incubations for 1 h at
RT were performed: ﬁrst with rabbit anti-human Ab (1:500,
D54D2, Cell Signaling Technology, Danvers, MA, USA), second with
biotinylated horse anti-rabbit (1:500, Vector Laboratories,
Burlingame, CA, USA) and third with streptavidin-horseradish per-
oxidase (1:2500, Sigma–Aldrich). Each incubation step was sepa-
rated by thorough washes with PBS 0.05% Tween 20 and PBS.
Finally, the detection of Ab was achieved by adding a solution con-
taining 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
diammonium salt (ABTS, Sigma–Aldrich), which induced a colori-
metric reaction read at 405 nm. The standard curve was obtained
using known concentrations of human Ab1–42 (American Peptide
Company, Sunnyvale, CA, USA) that ranged from 0.1 to 100 ng/lL
(considering the linearity of the assay). The levels of IFN-a were
measured in 1 lL of CSF, using the commercially available Mouse
IFN alpha Platinum ELISA kit (Affymetrix, eBioscience, Vienna,
Austria), according to the manufacturer’s instructions. The stan-
dard curve was obtained using known concentrations of mouse
IFN-a that ranged from 31.3 to 2000 pg/mL.
2.10. Immunoﬂuorescent staining for Ab peptides
Serial sections of frozen brain (coronal sections) with a thick-
ness of 20 lm were cut in the cryostat and collected to
SuperFrost Plus slides (ThermoFisher Scientiﬁc). Sections were
then ﬁxed for 20 min in 4% PFA (Panreac), at RT. A step of antigen
retrieval was performed afterwards, by heating the tissue sections
for 20 min in 10 mM, pH 6.0, acetic acid (Sigma–Aldrich). After a
blocking step for 1 h at RT, with a solution of 0.5% bovine serum
albumin (BSA, Sigma–Aldrich) in PBS 0.3% Triton X-100 (Sigma–
Aldrich) (PBS-T), the tissue sections were incubated, overnight,
with the primary antibody rabbit anti-human Ab (1:1000,
D54D2, Cell Signaling) diluted in blocking solution. After this per-
iod, the sections were rinsed in PBS-T and incubated with a sec-
ondary antibody conjugated to Alexa-594 (1:500, Invitrogen)
diluted in PBS-T for 1 h at RT. Finally, after incubation in a solution
of 4,6-diamidino-2-phenylindole (DAPI, 1:1000, Invitrogen) in PBS
for 5 min at RT, the sections were washed with PBS, and mounted
in Shandon Immu-Mount (ThermoFisher Scientiﬁc). Fluorescence
analysis and image capture were performed using a conventional
ﬂuorescence microscope (BX61; Olympus).
2.11. Immunohistochemistry for glial ﬁbrillary acidic protein (GFAP)
and ionized calcium-binding adapter molecule 1 (IBA1)
To assess the morphology of astrocytes and the number of
microglia/macrophages from the DG of the dHPC, 10 lm thick
coronal brain sections were deparafﬁnized and antigen retrieval
was performed by heating the tissue sections for 20 min in10 mM acetic acid solution, pH 6.0 (Sigma–Aldrich). Next, tissue
peroxidases were inactivated, by immersion in a 0.3% H2O2 solu-
tion for 30 min, and a blocking step was performed by incubation
in a PBS-T 0.5% BSA solution. Sections were later incubated over-
night, at RT, with rabbit anti-mouse GFAP (1:200, Dako, Golstrup,
Denmark) or rabbit anti-mouse IBA1 (1:300, Wako Chemicals
GmbH, Neuss, Germany) antibodies diluted in blocking solution
and, in the following day, rinsed in PBS-T and incubated with
biotinylated goat polyvalent antibody (UltraVision Large Volume
Detection System, ThermoFisher Scientiﬁc) for 1 h at RT. Finally,
after rinsing in PBS-T, sections were further incubated for 1 h with
streptavidin- horseradish peroxidase (UltraVision, ThermoFisher
Scientiﬁc), rinsed again in PBS and exposed to a
3,3-diaminobenzidine solution (Sigma–Aldrich) for 10 min. After
a thorough wash with PBS, sections were dried and mounted in
Entellan (Merck, Darmstadt, Germany). The morphology of 10
astrocytes (GFAP+ cells) located in the DG of the dHPC of each
mouse (N = 30 astrocytes/group) was assessed using an optical
microscope (BX51TF, Olympus) coupled to a camera (U-TV1X-2,
Olympus) and with the NeuroLucida software (Olympus). The sam-
ples were given a code name so that the morphology could be
assessed by an investigator who was blinded to the experiment.
Data was analyzed with the NeuroExplorer software (Olympus).
The number of microglia/macrophages in the DG of the dHPC
was assessed in serial brain sections and the number of cells per
mm2 was calculated (N = 4/group at 3 and 5–6 months, and
N = 5/group at 11–12 months).2.12. Statistical analysis
Values are reported as mean ± standard error of mean (SEM).
The number of biological replicates (N) of the representative inde-
pendent experiments is speciﬁed in the legend of each ﬁgure.
Statistical signiﬁcant differences between groups were determined
using the parametric repeated measures two-way ANOVA with
Bonferroni post hoc test (two-tailed) or the non-parametric
two-tailed Mann Whitney test and Kruskal–Wallis with Dunns’
multiple comparison test (two-tailed). Values were considered to
be statistically signiﬁcant for p < 0.05 (⁄), p < 0.01 (⁄⁄) and
p < 0.001 (⁄⁄⁄). Simple correlations were obtained by regression
analysis, using the Pearson’s correlation test, and results were con-
sidered to be statistically signiﬁcant for p < 0.05 (two-tailed).
Regression models (two-tailed) were designed and run in Matlab
R2009b (7.9.0.529, Mathworks, Natick, MA, USA). To avoid
collinearity, the independent variables age and IFN-a were cen-
tered, considering for that the respective mean values. To verify
the statistical signiﬁcance of the interactions between the different
predictors, four interaction terms were created (age*genotype,
age*IFN-a, genotype*IFN-a and age*genotype*IFN-a). No animals
were excluded from the analysis.3. Results
3.1. Age-associated memory decline was anticipated in J20 mice
The MWMwas used to test the performance of WT and J20 mice
in a spatial reference-memory task at 3, 5–6 and 11–12 months of
age (Fig. 1A and B). At 3 months, WT mice took signiﬁcantly less
time to ﬁnd the hidden platform, when compared to
age-matched J20 mice (Fig. 1B). At the ages of 5–6 months and
11–12 months, the differences between WT and J20 mice became
smaller; still, at 11–12 months, J20 mice presented a signiﬁcantly
worst performance than WT mice at day 5 of the MWM (Fig. 1B).
No statistical signiﬁcant differences were observed in terms of
swimming speed in the MWM, when comparing mice of different
Fig. 1. Cognitive performance, Ab pathology and microarray analysis of the CP of WT and J20 mice at 3, 5–6 and 11–12 months. (A) Cognitive performance and the level and
state of aggregation of Ab peptides were assessed in the brain of male WT and J20 mice, at the ages of 3, 5–6, 11–12 months. RNA was isolated and puriﬁed from samples of CP
extracted from all the brain ventricles of each WT or J20 mice. RNA samples from the CP of WT mice at 3 (N = 3), 5–6 (N = 4) and 11–12 (N = 6) months, and of J20 mice at 3
(N = 4), 5–6 (N = 4) and 11–12 (N = 3) months were used to analyze the transcriptomic changes by microarray. (B) Assessment of the performance in the MWM during the
light phase of the diurnal cycle, showed that J20 mice present a severe impairment in spatial reference-memory already at 3 months, when compared to age-matched WT
mice; however, the differences between WT and J20 mice in the MWM test are lessen at 5–6 and at 11–12 months, mostly due to the worst performance of WT mice at these
ages. (C) The level of Abwas measured in CSF samples fromWT and J20 mice; no differences were found between the levels of Abmeasured in the CSF of J20 mice at different
ages. (D) Staining for Ab in the dHPC revealed, in J20 mice only, an initial staining predominantly in the CA3 region, at 3 months, and a progressive increase in the level and
degree of extracellular aggregation of Ab peptides with aging, mostly in the molecular layer of the dHPC. (E) The number of signiﬁcantly (p < 0.05) up-(red) and down-
regulated (green) genes in the CP of J20 mice was obtained by normalizing to the expression levels of the corresponding genes in the CP of age-matched WT mice. There was
an age-dependent increase in the number of genes whose expression was signiﬁcantly altered in the CP of J20 mice. (F) After comparing the signiﬁcantly altered genes in the
CP of J20 at 3 vs 5–6 months, at 5–6 vs 11–12 months and at 3 vs 11–12 months, we found a common expression of 6, 42 and 16 genes, respectively; however, we found no
commonly altered genes after overlapping the CP transcriptomic changes of J20 mice at 3, 5–6 and 11–12 months. Results are presented as mean ± SEM [at 3 months,
N (WT) = 16 and N (J20) = 8; at 5–6 months, N (WT) = 8 and N (J20) = 10; at 11–12 months, N (WT) = 23 and N (J20) = 15] in (B); *p < 0.05, **p < 0.01 and ***p < 0.001; Repeated
measures two-way ANOVA, with Bonferroni post hoc test (two-tailed). Results are presented as mean ± SEM [at 3 months, N (WT) = 7 and N (J20) = 5; at 5–6 months,
N (WT) = 7 and N (J20) = 9; at 11–12 months, N (WT) = 7 and N (J20) = 9] in (C); Kruskal–Wallis with Dunns’ multiple comparison test (two-tailed). Scale bars indicate
100 lm in (D).
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loid pathology in J20 mice, we measured the levels of Ab in the CSF
and evaluated the degree of Ab aggregation and deposition in the
dHPC (Fig. 1C and D). There were no statistically signiﬁcant differ-
ences between the levels of Ab in the CSF of J20 mice at different
ages (Fig. 1C); yet, there was a progressive accumulation of Ab
and increased plaque burden in the dHPC of J20 mice with aging
that was more obvious at 11–12 months (Fig. 1D). No Ab was
detected in the CSF or in the brain of WT mice (Fig. 1C and D).
3.2. Age and Ab impacted differently on the CP transcriptome of WT
and of J20 mice
The changes in the CP transcriptome of J20 mice were assessed
by microarray at 3, 5–6 and 11–12 months of age and normalized
to the changes observed in age-matched WT mice (Fig. 1A). The
highest number of up- and down-regulated genes in the CP of
J20 mice was observed at 11–12 months (Fig. 1E). Of notice, wefound no commonly altered genes after overlapping the CP tran-
scriptomic changes of J20 mice at 3, 5–6 and 11–12 months
(Fig. 1F). Moreover, we found few commonly altered genes when
comparing the transcriptomic changes in the CP of J20 mice two
ages at a time (Fig. 1F). The ten most up- or down-regulated genes
in the CP of J20 mice (Table 1) revealed alterations in genes that are
involved in the functions classically attributed to the CP, such as
the modulation of the CSF’s composition, and that regulate the sur-
vival of CP cells and the maintenance of the barrier integrity
(Table 1). We also analyzed the effect of aging, per se, in the CP
transcriptome, by normalizing the changes observed in WT or J20
mice at 11–12 months to that of 3 months-old mice of the same
genotype (Supplementary Figs. 2 and 3). Interestingly, we found
a consistent alteration in the expression of genes that regulate
the cellular circadian rhythm in the 11–12 months-old mice, which
is describe in detail in the Supplementary data (Supplementary
Figs. 2 and 3 and Supplementary Tables 1 and 2). Surprisingly,
when considering all the analyzed data sets and comparisons
Table 1
Most altered genes in the CP of J20 mice (normalized to age-matched littermate WT mice).
Up-regulated genes Down-regulated genes
Accession
number
Entrez Gene name
(Mus musculus)
Gene
symbol
Fold
change
p-
value
Accession
number
Entrez Gene name (Mus musculus) Gene
symbol
Fold
change
p-
value
3 months (J20 vs WT)
NM_011638.3 Transferrin receptor Tfrc 1.64 0.007 NM_011066.1 Period circadian clock 2 Per2 1.52 0.019
NM_011909.1 Ubiquitin speciﬁc
peptidase 18
Usp18 1.43 0.017 NM_001033302.1 Circadian associated repressor of
transcription
Ciart 1.38 0.024
NM_019498.1 Olfactomedin 1 Olfm1 1.33 0.011 NM_008504.2 Granzyme M (lymphocyte metase 1) Gzmm 1.36 0.027
NM_008728.2 Natriuretic peptide
receptor 3
Npr3 1.32 0.001 NM_015750.1 Sialidase 2 (cytosolic sialidase) Neu2 1.33 0.038
NM_011819.1 Growth differentiation
factor 15
Gdf15 1.32 0.026 NM_053147.2 Prostaglandin I2 (prostacyclin)
synthase
Ptgis 1.31 0.021
NM_001039086.1 Rap guanine
nucleotide exchange
factor (GEF) 1
Rapgef1 1.28 0.007 NM_008968.2 TSC22 domain family, member 3 Tsc22d3 1.30 0.012
NM_013769.1 Tight junction protein
3
Tjp3 1.24 0.038 NM_001077364.1 DEAD (Asp-Glu-Ala-Asp) box helicase
17
Ddx17 1.30 0.044
NM_009423.2 Tnf receptor-
associated factor 4
Traf4 1.22 0.014 NM_148941.1 ELOVL fatty acid elongase 4 Elovl4 1.29 0.009
NM_020278.2 Leucine-rich, glioma
inactivated 1
Lgi1 1.21 0.025 NM_011072.2 Proﬁlin 1 Pfn1 1.24 0.039
NM_138314.1 NME/NM23 family
member 7
Nme7 1.21 0.049 XM_354652 3-hydroxyanthranilate 3,4-
dioxygenase
Haao 1.25 0.021
5–6 months (J20 vs WT)
NM_033373.1 Keratin 23 (histone
deacetylase inducible)
Krt23 1.48 0.008 NM_198110.1 Guanine nucleotide binding protein-
like 3 (nucleolar)-like
Gnl3l 1.46 0.028
NM_021389.3 SH3-domain kinase
binding protein 1
Sh3kbp1 1.37 0.011 NM_007751.1 Cytochrome c oxidase subunit VIIIb Cox8b 1.44 0.007
NM_010789.1 Meis homeobox 1 Meis1 1.32 0.008 NM_011213.1 Protein tyrosine phosphatase, receptor
type, F
Ptprf 1.30 0.012
NM_138955.2 ATP-binding cassette,
sub-family G (WHITE),
member 4
Abcg4 1.29 0.010 NM_010024.1 Dopachrome tautomerase Dct 1.30 0.006
NM_021399 B-cell CLL/lymphoma
11B (zinc ﬁnger
protein)
Bcl11b 1.29 0.041 NM_053110.2 Glycoprotein (transmembrane) nmb Gpnmb 1.26 0.042
NM_024440.1 Derlin 3 Derl3 1.26 0.005 NM_028756.2 Solute carrier family 35, member A5 Slc35a5 1.26 0.005
NM_021391.2 Protein phosphatase 1,
regulatory (inhibitor)
subunit 1A
Ppp1r1a 1.26 0.040 NM_026002 Metadherin Mtdh 1.25 0.022
NM_011807 Discs, large homolog 2
(Drosophila)
Dlg2 1.25 0.037 NM_133995.1 Ureidopropionase, beta Upb1 1.21 0.006
NM_007669.2 Cyclin-dependent
kinase inhibitor 1A
(p21, Cip1)
Cdkn1a 1.24 0.047 NM_023805.2 Solute carrier family 38, member 3 Slc38a3 1.20 0.031
NM_010630.1 Kinesin family
member C2
Kifc2 1.23 0.033 NM_145979.1 Chromodomain helicase DNA binding
protein 4
Chd4 1.20 0.045
11–12 months (J20 vs WT)
NM_007393.1 Actin beta Actb 2.30 0.033 NM_008786.1 Protein-L-isoaspartate (D-aspartate) O-
methyltransferase 1
Pcmt1 1.84 0.048
NM_198110.1 Guanine nucleotide
binding protein-like 3
(nucleolar)-like
Gnl3l 1.95 <0.001 NM_009842.3 CD151 molecule (Raph blood group) Cd151 1.68 0.036
NM_001081642.1 X-linked lymphocyte-
regulated 4A
Xlr4a 1.76 0.023 NM_022331.1 Homocysteine-inducible, endoplasmic
reticulum stress-inducible, ubiquitin-
like domain member 1
Herpud1 1.61 0.019
NM_145470.2 DEP domain
containing MTOR-
interacting protein
Deptor 1.53 0.024 NM_012002.1 COP9 signalosome subunit 6 Cops6 1.60 0.021
NM_133903.2 Spondin 2,
extracellular matrix
protein
Spon2 1.51 0.016 NM_183187.2 Family with sequence similarity 107,
member A
Fam107a 1.58 0.014
XM_196324.2 Deafness, autosomal
recessive 31
Dfnb31 1.47 0.005 NM_007472.1 Aquaporin 1 (Colton blood group) Aqp1 1.52 0.028
NM_054071.1 Fibroblast growth
factor receptor-like 1
Fgfrl1 1.47 0.012 NM_008947 Proteasome (prosome, macropain) 26S
subunit, ATPase, 1
Psmc1 1.52 0.012
NM_013882.1 G-2 and S-phase
expressed 1
Gtse1 1.46 0.004 NM_008610.1 Matrix metallopeptidase 2 (gelatinase
A)
Mmp2 1.50 0.008
NM_016972.2 Solute carrier family 7,
member 8
Slc7a8 1.44 0.008 NM_007413.2 Adenosine A2b receptor Adora2b 1.50 0.047
NM_001080126.1 Caspase 8, apoptosis-
related cysteine
peptidase
Casp8 1.43 0.031 NM_008504.2 Granzyme M (lymphocyte metase 1) Gzmm 1.49 0.003
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ied to a maximum fold-increase of 3.01 and fold-decrease of 3.45
(Table 1 and Supplementary Tables 1 and 2).
3.3. The pattern of changes in the CP transcriptome of J20 mice varied
with age
Using the gene network analysis computed by the IPA software,
we were able to establish a list of the 5 most altered gene net-
works, and associated biological functions, at each age in the CP
of J20 mice (Fig. 2A–F). Of notice, this analysis revealed that the
most altered gene network is different at each age
(Fig. 2B, D and F). At 3 months, at least two of the altered gene net-
works were involved in the regulation of one of the following bio-
logical functions: molecular transport, metabolism of small
molecules, cell-to-cell signaling/endocrine system function and
cell death/survival (Fig. 2A). At 5–6 months of age, in addition to
the alterations in the genes of network 5 (Fig. 2C) already affected
at 3 months (Fig. 2A), the main biological functions and processes
found to be altered were related with the hematological system,
inﬂammatory and humoral immune responses and cellular mor-
phology and motility (gene networks 1–4, Fig. 2C). Of notice, those
alterations in inﬂammation/immune-related pathways at 5–
6 months were sustained at 11–12 months, since the most altered
gene network in the CP of 11–12 months-old J20 mice regulated
the inﬂammatory and antimicrobial responses (gene network 1,
Fig. 2E) and included, as central modulators, the genes interferon
beta 1 (Ifnb1) and signal transducer and activator of transcription
1 (Stat1) (Fig. 2F). The gene networks 2–5, affected at 11–
12 months, showed again alterations in processes such as small
molecule biochemistry, molecular transport and cellular signaling,
movement and survival (Fig. 2E).
3.4. Type I and II IFN responses were altered in the CP of J20 mice
Taking into account the previous alterations, particularly those
regarding gene pathways involved in the regulation of the inﬂam-
matory/immune responses in the CP of J20, we next pursued the
underlying transcriptional regulators that could be responsible
for such alterations in gene expression (Fig. 3 and Supplementary
Table 3). For that analysis, we used the IPA Upstream Regulator
application, that computed an activation z-score predictive of the
activation status of a given transcriptional regulator, taking into
account the expression level of the corresponding downstream tar-
get genes in the CP of J20 mice at each age (Fig. 3A). Using the ﬁve
regulators with highest z-score and the ﬁve regulators with lowest
z-score (Supplementary Table 3), this analysis allowed the assem-
bly of gene interactomes (Fig. 3B–D). At 3 months, this approach
discriminated the genes Toll-like receptor 9 (Tlr9), interferon regu-
latory factor 7 (Irf7) and interferon (alpha and beta) receptor 1Table 2
Main effects of age, genotype and IFN-a levels in the CSF, alone (model 1) and taking into a
latency to platform in the MWM test.
Independent variables and interactions Latency (model 1)
b p
Age 2.5840 0.3372
Genotype 36.853 <0.0001
IFN-a 0.8746 0.0087
Age*Genotype Not included
Age*IFN-a
Genotype*IFN-a
Age*Genotype*IFN-a
WT mice: N (3 months) = 12; N (5–6 months) = 7; N (11–12 months) = 9.
J20 mice: N (3 months) = 5; N (5–6 months) = 9; N (11–12 months) = 8.
No collinearity was observed between independent variables.(Ifnar1), all of them predicted to be up-regulated in the CP of J20
mice, when compared with age matched WT mice (Fig. 3A and
B). Surprisingly, at the ages of 5–6 and 11–12 months, interferon
gamma (Ifng) presented a low activation z-score that suggested a
possible down-regulation of this gene in the CP of J20 mice
(Fig. 3A, C and D). Noticeably, the inactivation of the
Ifng-regulated pathway was predicted to affect the expression of
18 target genes at 5–6 months (Fig. 3C and Supplementary
Table 3), an effect that was even more marked at 11–12 months,
affecting 25 downstream genes/molecules (Fig. 3D and
Supplementary Table 3).
To conﬁrm and complement the array data, the expression of
type I IFN-related genes [Tlr9, Ifnar1, Irf7, interferon alpha 1
(Ifna1) and interferon beta 1 (Ifnb1)] and of type II IFN-related
genes [Ifng and intercellular adhesion molecule 1 (Icam1)] was
measured by qRT-PCR (Fig. 4A–G). Once again, we observed an
overexpression of Tlr9, Ifnar1, Irf7 and Ifnb1, in the CP of J20 mice
at 3 months, when compared with WT mice; together with Ifna1,
these genes remained highly expressed in the CP of J20 mice at
5–6 months when compared to 3 months-old WT mice (Fig. 4A–
E). In the CP of WT mice, despite the unaltered expression of Irf7,
Ifna and Ifnb1 (Fig. 4C–E) at different ages, we observed a signiﬁ-
cant overexpression of Tlr9 and Ifnar1 at 11–12 months, when
compared to the 3 months-old mice of the same genotype
(Fig. 4A and B). The genes Ifng and Icam1, which are related with
a type II IFN response, were also signiﬁcantly overexpressed at
3 months in the CP of J20 mice, when compared to age-matched
WT mice (Fig. 4F and G). On the other hand, at 5–6 months, there
was a signiﬁcant down-regulation of Ifng in the CP of J20 mice,
when compared to the expression levels at 3 months in J20 and
at 5–6 months in WT mice, which was maintained at 11–
12 months (Fig. 4F).
Next, to discriminate the speciﬁc contribution of CP epithelial
cells to the expression of type I or type II IFN genes in AD, we per-
formed primary cultures of CP epithelial cells on a transwell sys-
tem (to mimic the in vivo tight and polarized arrangement that
these epithelial cells present in the blood–CSF barrier, Fig. 4H),
and stimulated these cells at the apical membrane, which mimics
the CSF-side, with 1 lM Ab1–42. We observed that in response to
Ab1–42, the CP epithelial cells signiﬁcantly overexpressed the type
I IFN genes Tlr9 and Ifna1, but not the type II IFN gene Ifng
(Fig. 5I–K).
3.5. Aging altered the pattern of type I and II IFN gene expression in the
dHPC of WT and of J20 mice
To further investigate the IFN response at the brain parench-
yma, we measured the expression of the same type I and II IFN
genes in the dHPC of WT and J20 mice at different ages (Fig. 5A–
G). As observed before in the CP of J20 mice, there was anccount the interactions between independent variables (model 2), as predictors of the
Latency (model 2)
R2 (adjusted) b p R2 (adjusted)
0.6712 1.7302 0.5006 0.7177
35.962 <0.0001
0.4878 0.2056
15.595 0.0038
0.0957 0.8435
0.2905 0.7038
0.3214 0.7405
Fig. 2. Top ﬁve gene networks, and respective biological functions, speciﬁcally altered in the CP of J20 mice at different ages. The Ingenuity Pathway Analysis setup
computed the ﬁve most altered gene networks in the CP of J20 mice at 3 (A), 5–6 (C) and 11–12 (E) months, on the basis of the signiﬁcantly up- (red) and down-regulated
(green) genes, obtained after normalization to the expression levels in age-matched WT mice. An interaction scheme was assembled with the genes that composed the most
altered network in the CP of J20 mice at 3 (B), 5–6 (D) and 11–12 (F) months.
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3 months, when compared to age-matched WT mice, that was sta-
tistically signiﬁcant for Tlr9, Ifna1 and Ifnb1 (Fig. 5A, D and E).
Additionally, we observed a progressive increase in the expression
of all type I IFN genes, with aging, in the dHPC of WT mice, which
was statistically signiﬁcant at 11–12 months, when compared to
the expression levels of WT mice at 3 months (Fig. 5A–E).
Regarding the expression of type II IFN genes in the dHPC
(Fig. 5F and G), even though there was an increased expressionof Icam1 in 11–12 months-old WT mice (Fig. 5G), no changes were
observed on the levels of Ifng expression at the different ages
(Fig. 5F).
In an attempt to unravel the speciﬁc contribution of different
brain cell populations to the overexpression of type I and II IFN
genes, we measured the expression of Tlr9, Ifna1 and Ifng in pri-
mary cultures of astrocytes and of neurons, at different time points
upon stimulation with vehicle or 1 lM Ab1–42. However, no statis-
tical signiﬁcant differences were observed when comparing
Fig. 3. Interactome of altered transcriptional regulators predicted an early activation of a type I IFN response and a later inactivation of a type II IFN response, in the CP of J20
mice. (A) The Ingenuity Upstream Regulator Analysis computed an activation z-score for the transcriptional regulators that were predicted to modulate the gene expression
alterations in the CP of J20 at different ages, after normalization to the expression levels in the CP of age-matched WT mice. A gene interactome was assembled at 3 (B), 5–6
(C) and 11–12 (D) months, using the ﬁve transcriptional regulators with highest activation z-score and the ﬁve transcriptional regulators with lowest activation z-score
(Supplementary Table 3), as well as the signiﬁcantly altered genes under their regulation, in each dataset. (B) The gene interactome at 3 months indicated an activation of
TLR9, IRF7 and IFNAR1, characteristic of a type I IFN response. (C) At 5–6 months, the gene interactome underlined a down-regulation of IFN-c, impacting on 18 downstream
genes. (D) The down-regulation of IFN-c was sustained at 11–12 months and its effect was even more pronounced, inﬂuencing the expression of 25 target genes.
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Fig. 4).
3.6. Early activation of astrocytes and microglia was observed in the
dHPC of J20 mice
To have a different readout of the inﬂammatory response in the
dHPC of WT and J20 mice at different ages, we measured the
expression of Gfap and Iba1, as well as the morphology of astro-
cytes and the number of microglia/macrophages from the DG of
the dHPC, based on the staining for GFAP and IBA1, respectively
(Fig. 5H–K). There was a signiﬁcant overexpression of Gfap and
Iba1 in the dHPC of J20 mice, at 3 months, when compared to the
expression levels in age-matched WT mice (Fig. 5H and J). The
expression of Gfap was also signiﬁcantly increased in the dHPC of
WT mice at 11–12 months (Fig. 5H). Regarding the morphological
characterization of astrocytes, overall, we observed that astrocytes
from the dHPC of J20 mice presented a more ramiﬁed phenotype at
3 months, whereas, in the WT mice, these morphological alter-
ations were observed at the age of 5–6 months (Fig. 5I). In that
sense, except for the number of processes, a signiﬁcant increase
in the values of the analyzed astrocytic morphological parameters(length of individual processes, total surface and number of end-
ings) was observed in astrocytes from the DG of J20 mice at
3 months, when compared to 3 months-old WT mice and to 5–
6 months-old J20 mice (Fig. 5I). Noticeably, at 5–6 months, the
astrocytes from the DG of WT mice presented more processes
and were larger and more ramiﬁed than those of 5–6 months-old
J20 mice and of 3 months- and 11–12 months-old mice of the same
genotype (Fig. 5I). Concerning the quantiﬁcation of microglia/-
macrophages, there was a signiﬁcant increase in the number of
IBA1+ cells per mm2 in the DG of the dHPC of J20 mice at 11–
12 months, when compared to all other groups (Fig. 5K).
3.7. Increased level of IFN-a in the CSF was correlated with a worst
performance in the MWM
The level of IFN-awas measured in the CSF of WT and J20 mice,
at different ages (Fig. 6A). Although not signiﬁcant, we observed a
tendency for an increased level of IFN-a in the CSF of J20 mice,
when compared to 3 months-old WT mice, which was sustained
over time (Fig. 6A). Interestingly, we observed a signiﬁcant
increase in the level of IFN-a in the CSF of WT mice at 5–6 and
at 11–12 months, when compared to 3 months-old WT mice
Fig. 4. CP epithelial cells contributed differently to the overexpression of type I and II IFN genes in response to increased levels of Ab peptides. (A–G) The expression of type I
and II IFN genes in the CP was measured by qRT-PCR. Except for Ifna1, all the genes were signiﬁcantly overexpressed in the CP of J20 mice at 3 months when compared to the
expression in age-matched WT. At 5–6 months, the overexpression of Tlr9 (A), Ifnar1 (B) and Ifnb1 (E) was maintained in the CP of J20 mice, along with a signiﬁcant
overexpression of Ifna1 (D). Also in the CP of J20 mice at 5–6 months, there was a signiﬁcant down-regulation of Ifng (F), when compared to expression levels in J20 mice at
3 months and in WT mice at 5–6 months. (F, G) Both the expression of Ifng and Icam1 were signiﬁcantly decreased in the CP of J20 mice at 11–12 months, when compared to
the expression levels at 3 months. (A, B) In the CP of WT mice, we observed a signiﬁcant overexpression of Tlr9 and Ifnar1 at 11–12 months, when compared to the expression
levels at 3 months. (H-K) Treatment of primary cultures of CP epithelial cells, which are composed by P 95% of TTR+ cells, with 1 lM Ab1–42 for 60 h induced a signiﬁcant
overexpression of Tlr9 (I) and Ifna1 (J), but not of Ifng (K). Results regarding in vivo gene expression (A–G) are presented as mean ± SEM (N = 5/group); *p < 0.05 and **p < 0.01;
Kruskal–Wallis with Dunns’ multiple comparison test (two-tailed). Results regarding in vitro gene expression (I–K) are presented as mean ± SEM (N = 4/group); *p < 0.05; two-
tailed Mann Whitney test. Scale bar indicates 100 lm in (H).
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ﬁnd the hidden platform in the MWM (calculated as the average
time of latency to platform in the ﬁve days of the test) (Fig. 6B).
However, no signiﬁcant correlations were observed between the
levels of IFN-a and the latency to platform, when analyzing mice
at each age separately (Supplementary Fig. 5).
In order to analyze the effects of age, genotype and IFN-a levels
in the CSF as predictors of the spatial-reference memory perfor-
mance, we designed two regression models, to take into consider-
ation the main effects of the independent variables alone or all the
possible interactions (Table 2). The genotype and the levels of
IFN-a in the CSF, alone, were signiﬁcantly associated with alter-
ations in the performance in the MWM (model 1, Table 2).
However, when the interactions between the independent vari-
ables were considered, the genotype signiﬁcantly moderated the
relation between age and latency (model 2, Table 2). Of relevance,
when comparing the two models, the inclusion of the interaction
effects only represented an increment of 4.65% in the explained
variance of latency which was of 67.12% when no interactions were
included in the analysis.
4. Discussion
A progressive dysfunction of the blood–CSF barrier, which is
formed by the CP epithelial cells, is described in AD (Johanson
et al., 2004; Marques et al., 2013; Serot et al., 2012). To better
understand the speciﬁc alterations that occur at this barrier, we
used the J20 mouse model of AD (Baron et al., 2014; Mucke
et al., 2000) and investigated the changes in the CP transcriptome
at the ages of 3, 5–6 and 11–12 months, in comparison with
age-matched WT mice. We observed aging-induced alterations in
the CP transcriptome involving gene networks that regulate central
processes, such as the cellular circadian rhythm (Zhang and Kay,
2010), which are likely to affect the metabolic activity and cytoar-
chitecture of the blood–CSF barrier and to contribute to a defective
turnover of the CSF (He et al., 2014; Serot et al., 2012).
Regarding the CP of J20 mice, there was a sustained overexpres-
sion of genes that participate in the type I IFN response and a clear
decrease in the expression of Ifng, the major type II IFN gene. In alater age, but following the same direction, the CP of WT mice dis-
played an aging-associated increased expression of genes that
encode for two receptors that are involved in the type I IFN
response, Tlr9 and Ifnar1, but no signiﬁcant alterations in the
expression of genes involved in the type II IFN response.
Interestingly, the speciﬁc contribution of CP epithelial cells to the
overexpression of type I IFN genes, but not of the type II IFN gene
Ifng, shown to occur in vitro in response to Ab, led us to suggest that
the early overexpression of Ifng in the CP of J20 mice is due to
immune-related cells that inhabit and circulate in the CP stromal
compartment, a subject that warrants further investigation.
Interestingly, the strong activation of the type I IFN response both
in the CP and in the dHPC of J20 mice in early phases of the disease,
before marked amyloid deposition, together with the decreased
expression of Ifng in the CP at 5–6 and at 11–12 months, suggest
a possible interplay between type I and II IFN responses and Ab pla-
que formation. Moreover, although there is an apparent relation-
ship between the up-regulation of type I IFN genes, the early
overexpression of Gfap and Iba1 and increased astrocytic branching
in the dHPC, occurring ﬁrst in J20 and later in WT mice, it is still
unclear whether these observations are somehow connected. Of
notice, together with a lower expression of type I IFN genes a
decreased branching of astrocytes and increased number of
microglia/macrophages was also found in the DG of the dHPC of
J20 mice at 11–12 months. Intriguingly, also at 11–12 months,
along with a decreased inﬂammatory gene expression in the
dHPC, the behavioral impairment of J20 mice seems to become
milder, when compared to 3 months-old mice of the same geno-
type. Once again, whether there is a causal relationship between
these events in the brain of J20 mice and the deﬁcits in memory
is something that needs to be addressed in the future. In addition,
an age-dependent increased level of IFN-a in the CSF, observed
only in WT mice, is correlated with a poor performance in a spatial
reference-memory task. On the other hand, the J20 mice presented
no signiﬁcant alterations in the level of IFN-a in the CSF, which is
in agreement with their early and sustained memory impairment.
In fact, it is still controversial whether an early induction of a type I
IFN inﬂammatory response in the brain, followed by a reduced
type II IFN response, is beneﬁcial or detrimental for AD
Fig. 5. Aging altered the pattern of type I and II IFN gene expression, the morphology of astrocytes and the number of microglia/macrophages in the dHPC of WT and J20 mice.
(A–G) The expression of type I and II IFN genes in the dHPC was measured by qRT-PCR. A signiﬁcant overexpression of the type I IFN genes Tlr9 (A), Ifna1 (D) and Ifnb1 (E) was
observed in the dHPC of J20 mice at 3 months. On the other hand, at 11–12 months, except for Ifng (F), there was a statistically signiﬁcant overexpression of all genes in the
dHPC of WTmice. (H, I) To correlate the type I IFN gene expression with a different readout of the inﬂammatory status in the dHPC, the expression of Gfap and the morphology
of astrocytes was analyzed in the DG. (H) There was a signiﬁcant overexpression of Gfap in the dHPC of J20 andWTmice, at 3 and 11–12 months, respectively. (I) A signiﬁcant
increase in the size and number of endings of the astrocytic processes and, consequently, in the total surface of astrocytes, was observed in the DG of the dHPC of J20 mice at
3 months. In contrast, at 5–6 months and 11–12 months, the astrocytes of the DG of J20 mice presented less ramiﬁed processes and occupied a smaller surface. Noticeably,
the astrocytes from the DG of WTmice presented a signiﬁcant increase in all the analyzed morphological parameters at 5–6 months, but became signiﬁcantly smaller and less
ramiﬁed at 11–12 months. (J) There was a signiﬁcant overexpression of Iba1 in the dHPC of J20 mice at 3 months. (K) The number of IBA1+ cells per mm2 in the DG of 11–
12 months-old J20 mice was signiﬁcantly higher when compared to all other groups. Results regarding gene expression are presented as mean ± SEM (N = 5/group); *p < 0.05,
**p < 0.01 and ***p < 0.001; Kruskal–Wallis with Dunns’ multiple comparison test (two-tailed). Results regarding astrocytic morphology in (I) are presented as mean ± SEM
(N = 30 astrocytes/group) and microglia/macrophages in (K) are presented as mean ± SEM (N = 4/group at 3 and 5–6 months, and N = 5/group at 11–12 months); *p < 0.05,
**p < 0.01 and ***p < 0.001; Kruskal–Wallis with Dunns’ multiple comparison test (two-tailed). Scale bars indicate 100 lm (lower magniﬁcation) and 20 lm (higher
magniﬁcation) in (I) and 200 lm (lower magniﬁcation) and 50 lm (higher magniﬁcation) in (K).
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Taylor et al., 2014). Regarding the type II IFN response in AD, it
has been previously shown that overexpression of IFN-c boosts
the amyloidogenic processing of APP both in vitro and in vivo
(Blasko et al., 1999; Mastrangelo et al., 2009). In accordance, it
was recently suggested that a higher frequency of
IFN-c-producing T-cells in the brain of AD transgenic mice is asso-
ciated with increased glial activation and amyloid plaque forma-
tion, as well as with worst cognitive function (Browne et al.,
2013). However, there is also evidence of a beneﬁcial impact of
increased levels of IFN-c-producing T-cells in AD transgenic mice
at 9 months of age, namely by increased microglial activation,
increased Ab phagocytosis and decreased plaque burden in the
DG of the HPC (Monsonego et al., 2006). These divergent observa-
tions may be due to the speciﬁc effects of IFN-c overproduction at
different stages of brain pathology in AD, which prompts for a dee-
per characterization of the role of the type II IFN mediators in the
AD brain at different ages. On the other hand, concerning the type I
IFN response, a recent study showed that at the level of the CP of
22 months-old mice, increased levels of IFN-b signaling promoteincreased glial activation and impact on cognitive behavior
(Baruch et al., 2014). Moreover, it was suggested that an
aging-related central nervous system (CNS)-derived stimulus could
be in the genesis of a shift from a type II IFN into a type I IFN
response at the CP, and that this would compromise the
immune-surveillance of the brain by decreasing the levels of
IFN-c (Baruch et al., 2014; Kunis et al., 2013). Interestingly, even
in the absence of a viral infection, increased levels of type I IFN
cytokines in the brain, particularly IFN-a, lead to massive
encephalopathy, with marked meningoencephalitis, calcium min-
eralization, gliosis, and neurodegeneration (Akwa et al., 1998). In
the context of AD, others have shown that the genes encoding
for IFN-a and IFN-b are overexpressed in cultured neurons, upon
stimulation with Ab, and in cortical cells extracted from the brains
of AD patients, in a mechanism dependent on IRF7 and IFNAR1,
which is associated with decreased neuronal viability (Taylor
et al., 2014). Conversely, stimulation of the innate response with
the TLR9 agonists cytosine-guanosine-containing DNA
oligodeoxynucleotides (CpG DNA oligos), in two different mouse
models of AD, ameliorated both the pathologic hallmarks and the
Fig. 6. Age-dependent increased level of IFN-a in the CSF of WT mice was signiﬁcantly correlated with a worst memory function. (A) The level of IFN-a was signiﬁcantly
increased in the CSF of WT mice at 5–6 and 11–12 months, when compared to 3 months-old mice of the same genotype. Of notice, although not statistically signiﬁcant, a
tendency for an increased level of IFN-a was observed in the CSF of 3 months-old J20 mice, when compared to the levels measured in 3 months-old WT mice, which was
sustained over time. (B) A positive correlation between the level of IFN-a in the CSF of WT mice and the average time of latency to platform in the ﬁve days of the MWM (gray
to black dots) was observed. No correlation was found between the levels of IFN-a in the CSF and the latency to platform in J20 mice (pink to red dots). Results regarding the
measurement of IFN-a are presented as mean ± SEM [3 months: N (WT) = 12 and N (J20) = 5; 5–6 months: N (WT) = 7 and N (J20) = 8; 11–12 months: N (WT) = 9 and N
(J20) = 8]; *p < 0.05 and ***p < 0.001; Kruskal–Wallis with Dunns’ multiple comparison test (two-tailed). The Pearson’s correlation test was used to perform the analysis in (B)
and to calculate the associated R2 and p-value (two-tailed). Correlation was considered signiﬁcant for p < 0.05; N (WT) = 28 and N (J20) = 22.
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inﬂammatory side-effects (Scholtzova et al., 2009, 2014). Also,
increased production of IFN-b by astrocytes, upon speciﬁc TLR3
stimulation, was shown to affect the spontaneous activity of neu-
rons from the CA1 region of the HPC. This effect of IFN-b on neu-
ronal excitability was shown to be mediated by IFNAR1, due to
the lack of changes in the HPC of Ifnra1-null mice (Costello and
Lynch, 2013). Additionally, 9 months-old transgenic APP/PS1 mice
present higher levels of IFN-a in the brain, when compared to
age-matched WT mice (Taylor et al., 2014). Interestingly, our
results also suggest that, along with a possible impact on behavior,
an activation of a type I IFN response in the dHPC, in younger J20
mice and in 11–12 months-old WT mice may be linked with
changes in the astrocytes’ morphology. It is widely accepted that
increased levels of inﬂammatory molecules, whether in the circu-
lation or in speciﬁc regions of the CNS, can affect the morphology
and function of brain cells, especially of glial cells (Baron et al.,
2014; Ghosh et al., 2013). Astrocytes in particular seem to play a
central role in the inﬂammatory response and are good indicators
of the level of brain inﬂammation (Medeiros and LaFerla, 2013;
Wyss-Coray, 2006). Concurrently, the activation of astrocytes and
microglia was shown to occur before Ab plaque formation in the
HPC of J20 mice (Baron et al., 2014; Beauquis et al., 2014; Wright
et al., 2013) and that an increased microglial activation and clus-
tering, observed at 4 weeks of age in the HPC of these mice, pre-
cedes neuronal atrophy, decreased neurogenesis and a decrease
in the volume of the HPC (Fu et al., 2014). However, it is necessary
to further investigate whether the early induction of type I IFN
genes in the dHPC of J20 mice is directly promoting changes in glial
activation and Ab pathology. Moreover, it will be important to
explore the impact of increased level of type I IFN cytokines, such
as IFN-a, on the premature memory deﬁcits observed in this AD
mouse model and on the memory and cognitive impairments in
older WT mice.
Overall, this study reveals that structures such as the CP and the
dHPC may be key elements in the inﬂammatory signaling in the
CNS, by modulating the levels of IFNs, with a possible impact on
memory and cognition.Competing interests
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